Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.

Journal article

Ogbe A. et al, (2022), JCI Insight

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Journal article

Clemens SAC. et al, (2021), Nature Communications, 12

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.

Journal article

Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568

Corrigendum to: Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.

Journal article

Theiss-Nyland K. et al, (2021), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73, 1950 - 1950

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.

Journal article

Swanson PA. et al, (2021), Science translational medicine, eabj7211 - eabj7211

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Journal article

Flaxman A. et al, (2021), SSRN Electronic Journal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

Journal article

Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046

Load More